What is the address of Greenpharm?

The registered office of Greenpharm is located at Prof.Scharpélaan 64, 3130 Begijnendijk.

Is Greenpharm still active?

Yes. According to the CBE (30 October 2026) Greenpharm is active, legal situation “Normale toestand”, started on 18 October 2019.

Is Greenpharm registered on Peppol?

No, Greenpharm is currently not registered on the Peppol network.

What is the enterprise number of Greenpharm?

The enterprise number of Greenpharm is BE0736542972.

When was Greenpharm founded?

Greenpharm was founded on 18 October 2019.

Who are the directors of Greenpharm?

According to the 2025 annual accounts, the directors of Greenpharm are: Simon Scharpé, Dirk Hendriks.

Is Greenpharm a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 October 2019; 6 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Greenpharm make in 2025?

Greenpharm recorded a loss after taxes of € 2,822 in financial year 2025.

What is the revenue of Greenpharm?

As a small company, Greenpharm is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -2,392.

Greenpharm (Private Limited) - Begijnendijk

Dossier Greenpharm, printed on 30 October 2026 from databakkes.be/en/0736542972/greenpharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

Greenpharm from Begijnendijk, company number BE0736542972, closed financial year 2025 with a result of € -2,822 after tax. For that financial year Greenpharm recorded a gross margin of € -2,392 and equity of € 53,539. Compared with financial year 2024, the result moved from € -3,296 to € -2,822. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 3, 2026.

What it is worth Healthy

€ 53,539

▼ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -2,822

▲ 14 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 85,198

▼ 4% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -36,528.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 2,000

▼ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -4,285 Gross margin 2022: € -4,285 First fiscal year in the series	€ -3,278 Gross margin 2023: € -3,278 ▲ € 1,007 vs 2022 (€ -4,285) Favourable step	€ -2,870 Gross margin 2024: € -2,870 ▲ € 408 vs 2023 (€ -3,278) Favourable step	€ -2,392 Gross margin 2025: € -2,392 ▲ € 478 vs 2024 (€ -2,870) Favourable step	▲ € 478
Profit after taxes	€ -4,663 Profit after taxes 2022: € -4,663 First fiscal year in the series	€ -3,693 Profit after taxes 2023: € -3,693 ▲ € 970 vs 2022 (€ -4,663) Favourable step	€ -3,296 Profit after taxes 2024: € -3,296 ▲ € 397 vs 2023 (€ -3,693) Favourable step	€ -2,822 Profit after taxes 2025: € -2,822 ▲ € 474 vs 2024 (€ -3,296) Favourable step	▲ € 474
Equity	€ 63,351 Equity 2022: € 63,351 First fiscal year in the series	€ 59,658 Equity 2023: € 59,658 ▼ 6% vs 2022 (€ 63,351) Unfavourable step	€ 56,362 Equity 2024: € 56,362 ▼ 6% vs 2023 (€ 59,658) Unfavourable step	€ 53,539 Equity 2025: € 53,539 ▼ 5% vs 2024 (€ 56,362) Unfavourable step	▼ 5%
Total debts	€ 33,288 Total debts 2022: € 33,288 First fiscal year in the series	€ 31,658 Total debts 2023: € 31,658 ▼ 5% vs 2022 (€ 33,288) Favourable step	€ 32,054 Total debts 2024: € 32,054 ▲ 1% vs 2023 (€ 31,658) Unfavourable step	€ 31,658 Total debts 2025: € 31,658 ▼ 1% vs 2024 (€ 32,054) Favourable step	▼ 1%
Cash	€ 96,639 Cash 2022: € 96,639 First fiscal year in the series	€ 91,316 Cash 2023: € 91,316 ▼ 6% vs 2022 (€ 96,639) Unfavourable step	€ 88,416 Cash 2024: € 88,416 ▼ 3% vs 2023 (€ 91,316) Unfavourable step	€ 85,198 Cash 2025: € 85,198 ▼ 4% vs 2024 (€ 88,416) Unfavourable step	▼ 4%
Retained profit	€ -26,717 Retained profit 2022: € -26,717 First fiscal year in the series	€ -30,410 Retained profit 2023: € -30,410 ▼ € 3,693 vs 2022 (€ -26,717) Unfavourable step	€ -33,706 Retained profit 2024: € -33,706 ▼ € 3,296 vs 2023 (€ -30,410) Unfavourable step	€ -36,528 Retained profit 2025: € -36,528 ▼ € 2,822 vs 2024 (€ -33,706) Unfavourable step	▼ € 2,822
Balance sheet total	€ 96,639 Balance sheet total 2022: € 96,639 First fiscal year in the series	€ 91,316 Balance sheet total 2023: € 91,316 ▼ 6% vs 2022 (€ 96,639) Unchanged	€ 88,416 Balance sheet total 2024: € 88,416 ▼ 3% vs 2023 (€ 91,316) Unchanged	€ 85,198 Balance sheet total 2025: € 85,198 ▼ 4% vs 2024 (€ 88,416) Unchanged	▼ 4%

Key figures of Greenpharm, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Greenpharm?

What happened at Greenpharm in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 3, 2026 New annual accounts for financial year 2025: loss of € 2,822. Source: NBB ↗
Oct 18, 2019 New establishment in Begijnendijk. KBO
Oct 18, 2019 Start of the company according to the CBE. KBO

In short

From € 4,663 loss in 2022 to € 2,822 loss in 2025.

Original PDFs at the National Bank ↗

Management

Simon Scharpé Dirk Hendriks

Greenpharm

CellCarta

HistoGeneX Holding

Arsenal IO Belgium

Behind Greenpharm are Simon Scharpé and Dirk Hendriks. Dirk Hendriks is also behind CellCarta, HistoGeneX Holding, Arsenal IO Belgium and Hendriks Consulting Company.

Directors

According to the 2025 annual accounts

Simon Scharpé

Director

Dirk Hendriks

Director

Also active at: CellCarta, HistoGeneX Holding, Arsenal IO Belgium, Hendriks Consulting Company

Establishments

Establishment units

Physical locations of this company

Registered office

Prof.Scharpélaan 64

3130 Begijnendijk

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0736.542.972
VAT number: BE 0736.542.972
Registered office: Prof.Scharpélaan 64, 3130 Begijnendijk
Names & denominations: Greenpharm
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 18 October 2019
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗